Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level

NCT03488706 is registered in ClinicalTrials.gov with CellMaxLife as lead sponsor.

NCT NCT03488706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
Lead sponsor
CellMaxLife
Phase
Observational
Overall status
Unknown status
Start date
January 17, 2018
Completion date
June 2, 2021
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer